A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome
- 1Baylor College of Medicine, Houston, Texas, USA
- 2Children’s Hospital of Philadelphia, Pennsylvania, USA
- Correspondence to Professor J Jankovic, Parkinson’s Disease Center, and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, The Smith Tower, Suite 1801, 6550 Fannin, Houston, TX 77030, USA; josephj{at}bcm.tmc.edu
- Received 4 June 2009
- Revised 14 August 2009
- Accepted 17 August 2009
- Published Online First 1 September 2009
Abstract
Objective: To investigate the effects of topiramate on Tourette syndrome (TS).
Background: Dopamine-receptor-blocking drugs have been traditionally used to control tics in patients with TS, but these neuroleptics are associated with potentially limiting side effects.
Methods: This is a randomised, double-blind, placebo-controlled, parallel group study. To be included in the study, subjects required a DSM-IV diagnosis of TS, were 7–65 years of age, had moderate to severe symptoms (Yale Global Tic Severity Scale (YGTSS) ≥19), were markedly impaired as determined by the Clinical Global Impression (CGI) scale severity score of ≥4 and were taking no more than one drug each for tics or TS comorbidities.
Results: There were 29 patients (26 males), mean age 16.5 (SD 9.89) years, randomised, and 20 (69%) completed the double-blind phase of the study. The primary endpoint was Total Tic Score, which improved by 14.29 (10.47) points from baseline to visit 5 (day 70) with topiramate (mean dose 118 mg) compared with a 5.00 (9.88) point change in the placebo group (p = 0.0259). There were statistically significant improvements also in the other components of the YGTSS as well as improvements in various secondary measures, including the CGI and premonitory urge CGI. No differences were observed in the frequency of adverse events between the two treatment groups.
Conclusion: This double-blind, placebo-controlled trial provides evidence that topiramate may have utility in the treatment of moderately severe TS.
Footnotes
-
Funding The investigator-initiated study was supported by a grant from Ortho McNeil Janssen Scientific Affairs, LLC.
-
Competing interests None.
-
Ethics approval Ethics approval was provided by the Review Boards for Human Research of the participating institutions.
-
Patient consent Obtained.
-
Provenance and Peer review Not commissioned; externally peer reviewed.
